Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mini-ATG + TBI + fludarabine + cyclophosphamide conditioning for unrelated umbilical cord blood transplantation in pediatric acquired aplastic anemia
ChiCTR2400088868Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of antithymocyte globulin, fludarabine and cyclophosphamide in acquired aplastic anemia (AAA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: acute graft-versus-host disease rate and engraftment rate. Started Aug 2024; status: recruiting.
02
Drugs
antithymocyte globulinfludarabinecyclophosphamide
03
Conditions
acquired aplastic anemia (AAA)
Beyond the preview
Go deeper on ChiCTR2400088868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088868.